Stephen J. Hill - Feb 24, 2023 Form 4 Insider Report for Lyell Immunopharma, Inc. (LYEL)

Role: Chief Technical Ops. Officer
Signature: /s/ Hector Casab, as Attorney-in-Fact
Stock symbol: LYEL
Transactions as of: Feb 24, 2023
Transactions value $: $0
Form type: 4
Date filed: 2/28/2023, 05:21 PM
Previous filing: Mar 18, 2022
Next filing: Nov 20, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	LYEL	Common Stock						2.94K	Feb 24, 2023	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	LYEL	Option (right to buy)	Award	$0	+900K		$0.00	900K	Feb 24, 2023	Common Stock	900K	$2.13	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Shares acquired on May 18, 2022 under the Issuer's 2021 Employee Stock Purchase Plan.
F2	12.5% of the option shares shall vest on August 9, 2023, with the remaining option shares to vest in equal monthly installments over the following forty-two months.